Herwig Koppensteiner

Neuherberg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

Journal: The Journal of dermatological treatment

Published: August 07, 2026

Efficacy of abrocitinib and dupilumab on chronic hand eczema in patients with moderate-to-severe atopic dermatitis: a prespecified exploratory analysis of the phase 3 JADE DARE study.

Efficacy of abrocitinib and dupilumab on chronic hand eczema in patients with moderate-to-severe atopic dermatitis: a prespecified exploratory analysis of the phase 3 JADE DARE study.

Journal: Journal of the American Academy of Dermatology

Published: January 28, 2026

HIV-1 manipulates CD96 on CD4+ T cells to subvert antiviral immunity.

HIV-1 manipulates CD96 on CD4+ T cells to subvert antiviral immunity.

Journal: Science advances

Published: September 05, 2025

Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years.

Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 31, 2025

Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Journal: Dermatology and therapy

Published: April 26, 2025

Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis.

Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis.

Journal: Allergy

Published: June 28, 2024

Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays.

Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays.

Journal: Human gene therapy methods

Published: February 09, 2019

Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors.

Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors.

Journal: Molecular therapy. Methods & clinical development

Published: January 29, 2019

T cells with low CD2 levels express reduced restriction factors and are preferentially infected in therapy naïve chronic HIV-1 patients.

T cells with low CD2 levels express reduced restriction factors and are preferentially infected in therapy naïve chronic HIV-1 patients.

Journal: Journal of the International AIDS Society

Published: September 28, 2017

Virion encapsidated HIV-1 Vpr induces NFAT to prime non-activated T cells for productive infection.

Virion encapsidated HIV-1 Vpr induces NFAT to prime non-activated T cells for productive infection.

Journal: Open biology

Published: February 19, 2016

Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins.

Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins.

Journal: Scientific reports

Published: November 10, 2015

HIV-1 Nef and Vpu Interfere with L-Selectin (CD62L) Cell Surface Expression To Inhibit Adhesion and Signaling in Infected CD4+ T Lymphocytes.

HIV-1 Nef and Vpu Interfere with L-Selectin (CD62L) Cell Surface Expression To Inhibit Adhesion and Signaling in Infected CD4+ T Lymphocytes.

Journal: Journal of virology

Published: March 05, 2015

Showing 1-12 of 20

Last Updated: 09/26/2026